Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2017-08-30 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于召开2017年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2017 second extraordinary general meeting of shareholders for Jiangsu Sihuan Bioengineering Co., Ltd. It includes details about the meeting date, agenda items for shareholder voting, registration methods, and voting procedures. There is no financial data, earnings, or report content. The document is an announcement informing shareholders about the meeting and how to participate, not the actual meeting materials or results. The document length is 3477 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or notices about such meetings.
2017-08-30 Chinese
2017年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司 2017 年半年度报告全文" which translates to "Jiangsu Sihuan Bioengineering Co., Ltd. 2017 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, asset and liability status, investment analysis, and other comprehensive information typical of a semi-annual financial report. The document includes actual financial statements and substantive financial data for the half-year period of 2017. It is not a brief announcement or a certification letter but a full report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-30 Chinese
2017年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '江苏四环生物股份有限公司 2017 年半年度报告摘要' which translates to 'Jiangsu Sihuan Biological Co., Ltd. 2017 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period of 2017, including revenue, net profit, earnings per share, assets, and shareholder information. The document discusses the company's operating results, financial condition, and changes in consolidated subsidiaries. It explicitly states it is a half-year report summary, which is a form of an interim or quarterly report. The length is 3521 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-30 Chinese
独立董事关于关联方资金往来、对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of Jiangsu Sihuan Bio-technology Co., Ltd. regarding related party fund transactions and external guarantees. It references regulatory guidance (证监发（2003）56号文) about related party transactions and external guarantees. The content is a formal attestation and opinion on these matters, not a full audit report or annual report. It is a standalone audit-related statement focusing on compliance and internal checks, typical of an Audit Report / Information filing. The document length is short but contains substantive independent director opinions and verification, which aligns with the AR category rather than a mere announcement or certification. Therefore, the classification is AR with high confidence. H1 2017
2017-08-30 Chinese
关于为全资子公司申请银行贷款提供担保
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Jiangsu Sihuan Bio Co., Ltd. regarding the provision of a guarantee for a bank loan applied for by its wholly-owned subsidiary. It details the guarantee amount, terms, the subsidiary's financial status, and board approval. The document is short (1505 characters) and focuses on a specific financing-related event (loan guarantee). It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is an update on a financing activity related to capital structure (loan guarantee). Therefore, it fits best under Capital/Financing Update (CAP).
2017-08-30 Chinese
关于全资子公司申请银行贷款的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (582 characters) about a wholly-owned subsidiary applying for a bank loan, including loan amount, interest rate, and term. It mentions board approval and the need for shareholder meeting approval. There are no financial statements or detailed financial analysis. The document is an update on financing activity, specifically a loan application and guarantee. It is not a full financial report, audit, or earnings release. Given the content and length, it fits best under Capital/Financing Update (CAP).
2017-08-30 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.